IOVA vs UNH

Iovance Biotherapeutics' risk-reward profile has marginally improved due to strong Q4 2025 revenue beating estimates, demonstrating initial commercial traction for AMTAGVI with ~30% sequential growth and improving gross margins. This addresses key execution concerns regarding commercialization and manufacturing. Furthermore, positive early data for lifileucel in soft tissue sarcomas and the planne...

UnitedHealth Group (UNH) remains a healthcare titan, but its sheer scale and the highly regulated nature of its operations fundamentally limit its 10x growth potential within 3-5 years. The recent Optum Health operating loss of $278M in 2025 (compared to $7.77B income in 2024) is a significant concern, eroding the growth narrative that Optum once provided. Furthermore, the proposed 0.09% Medicare ...